Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 14/20 | 0.45 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.40 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337161 | 0.94 | PIK3CA (0.52) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL337167 | 0.84 | PIK3CA (0.54) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL337330 | 0.82 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL336411 | 0.82 | PIK3CA (0.54) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL799206 | 0.81 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL336652 | 0.80 | PIK3CA (0.53) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL336823 | 0.77 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL336812 | 0.77 | PIK3CA (0.58) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL336824 | 0.77 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG | |
| SCHEMBL336582 | 0.77 | PIK3CA (0.52) | PIK3CAPIK3CDPIK3CBPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | PIK3CA 22/4885PIK3CD 46/4885PIK3CB 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.